Connor, Clark & Lunn Investment Management (CC&L)’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $62.6M | Buy |
1,467,148
+659,779
| +82% | +$35.8M | 0.12% | 155 |
|
|
2026
Q1 | $50.7M | Sell |
807,369
-11,547
| -1% | -$924K | 0.12% | 173 |
|
|
2025
Q4 | $78.1M | Buy |
818,916
+559,969
| +216% | +$54.9M | 0.2% | 109 |
|
|
2025
Q3 | $25.3M | Buy |
258,947
+256,802
| +11,972% | +$26.6M | 0.08% | 223 |
|
|
2025
Q2 | $230K | Sell |
2,145
-105,935
| -98% | -$10.7M | ﹤0.01% | 1396 |
|
|
2025
Q1 | $10.9M | Buy |
108,080
+26,489
| +32% | +$2.67M | 0.05% | 306 |
|
|
2024
Q4 | $7.29M | Sell |
81,591
-137,165
| -63% | -$12.1M | 0.03% | 391 |
|
|
2024
Q3 | $18.3M | Buy |
218,756
+195,461
| +839% | +$15.4M | 0.09% | 179 |
|
|
2024
Q2 | $1.79M | Buy |
23,295
+11,664
| +100% | +$854K | 0.01% | 685 |
|
|
2024
Q1 | $797K | Sell |
11,631
-73,281
| -86% | -$4.71M | ﹤0.01% | 951 |
|
|
2023
Q4 | $4.91M | Buy |
+84,912
| New | +$4.53M | 0.02% | 425 |
|
|
2022
Q4 | – | Sell |
-165,073
| Closed | -$6.39M | – | 1226 |
|
|
2022
Q3 | $6.39M | Sell |
165,073
-2,771
| -2% | -$111K | 0.04% | 272 |
|
|
2022
Q2 | $6.26M | Sell |
167,844
-126,207
| -43% | -$5.14M | 0.04% | 270 |
|
|
2022
Q1 | $13M | Buy |
+294,051
| New | +$12.7M | 0.06% | 191 |
|
|
2021
Q3 | – | Sell |
-94,751
| Closed | -$4.05M | – | 1055 |
|
|
2021
Q2 | $4.05M | Sell |
94,751
-132,553
| -58% | -$5.58M | 0.02% | 397 |
|
|
2021
Q1 | $8.79M | Buy |
+227,304
| New | +$8.6M | 0.05% | 260 |
|
|
2020
Q4 | – | Sell |
-190,152
| Closed | -$7.27M | – | 903 |
|
|
2020
Q3 | $7.27M | Buy |
+190,152
| New | +$7.33M | 0.05% | 243 |
|
|
2020
Q1 | – | Sell |
-33,313
| Closed | -$1.51M | – | 1026 |
|
|
2019
Q4 | $1.51M | Buy |
+33,313
| New | +$1.39M | 0.01% | 470 |
|
|
2019
Q2 | – | Sell |
-7,813
| Closed | -$300K | – | 989 |
|
|
2019
Q1 | $300K | Buy |
+7,813
| New | +$298K | ﹤0.01% | 757 |
|
|
2018
Q1 | – | Sell |
-275,339
| Closed | -$6.83M | – | 721 |
|
|
2017
Q4 | $6.83M | Sell |
275,339
-196,775
| -42% | -$5.43M | 0.04% | 248 |
|
|
2017
Q3 | $13.8M | Sell |
472,114
-380,900
| -45% | -$10.5M | 0.08% | 171 |
|
|
2017
Q2 | $23.6M | Sell |
853,014
-86,370
| -9% | -$2.29M | 0.16% | 104 |
|
|
2017
Q1 | $23.4M | Buy |
939,384
+358,659
| +62% | +$8.72M | 0.15% | 108 |
|
|
2016
Q4 | $12.6M | Buy |
580,725
+351,125
| +153% | +$7.66M | 0.09% | 149 |
|
|
2016
Q3 | $5.46M | Buy |
+229,600
| New | +$5.48M | 0.04% | 237 |
|
|
2015
Q3 | – | Sell |
-119,766
| Closed | -$2.12M | – | 721 |
|
|
2015
Q2 | $2.12M | Buy |
119,766
+400
| +0.3% | +$7.15K | 0.02% | 233 |
|
|
2015
Q1 | $2.12M | Sell |
119,366
-36,300
| -23% | -$574K | 0.02% | 225 |
|
|
2014
Q4 | $2.06M | Buy |
155,666
+25,200
| +19% | +$322K | 0.02% | 223 |
|
|
2014
Q3 | $1.54M | Sell |
130,466
-22,000
| -14% | -$277K | 0.01% | 242 |
|
|
2014
Q2 | $2.07M | Buy |
152,466
+1,400
| +0.9% | +$18.2K | 0.01% | 242 |
|
|
2014
Q1 | $2.25M | Buy |
151,066
+46,100
| +44% | +$605K | 0.02% | 263 |
|
|
2013
Q4 | $1.34M | Buy |
104,966
+1,466
| +1% | +$17.3K | 0.01% | 321 |
|
|
2013
Q3 | $1.25M | Sell |
103,500
-41,700
| -29% | -$451K | 0.01% | 244 |
|
|
2013
Q2 | $1.42M | Buy |
+145,200
| New | +$1.23M | 0.01% | 229 |
|
Other funds holding BSX
Connor, Clark & Lunn Investment Management (CC&L)'s BSX Position: Q2 2026 in Review
Connor, Clark & Lunn Investment Management (CC&L) increased its Boston Scientific (BSX) stake by 82% in Q2 2026, buying an estimated $35.8M and bringing the position to 1,467,148 shares worth $62.6M. The position accounts for 0.12% of the portfolio, ranked #155.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BSX in Q2 2013 and has held it in 34 quarters since. The position peaked at $78.1M in Q4 2025. 1,472 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) held 1,467,148 shares of Boston Scientific worth $62.6M as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) bought 659,779 Boston Scientific shares in Q2 2026, an estimated $35.8M.
- Boston Scientific made up 0.12% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #155 holding.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Boston Scientific in Q2 2013 and has held it in 34 quarters since.
- Connor, Clark & Lunn Investment Management (CC&L)'s Boston Scientific position peaked at $78.1M in Q4 2025.
- 1,472 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.